Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2005 1
2006 2
2007 2
2008 1
2010 3
2011 2
2012 3
2013 2
2014 1
2015 7
2016 7
2017 5
2018 8
2019 4
2020 8
2021 12
2022 8
2023 13
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

90 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial).
Masuda J, Sakai H, Tsurutani J, Tanabe Y, Masuda N, Iwasa T, Takahashi M, Futamura M, Matsumoto K, Aogi K, Iwata H, Hosonaga M, Mukohara T, Yoshimura K, Imamura CK, Miura S, Yamochi T, Kawabata H, Yasojima H, Tomioka N, Yoshimura K, Takano T. Masuda J, et al. Among authors: futamura m. J Immunother Cancer. 2023 Sep;11(9):e007126. doi: 10.1136/jitc-2023-007126. J Immunother Cancer. 2023. PMID: 37709297 Free PMC article. Clinical Trial.
Comprehensive Genome profile testing in head and neck cancer.
Kuroki M, Iinuma R, Okuda H, Terazawa K, Shibata H, Mori KI, Ohashi T, Makiyama A, Futamura M, Miyazaki T, Horikawa Y, Ogawa T. Kuroki M, et al. Among authors: futamura m. Auris Nasus Larynx. 2023 Dec;50(6):952-959. doi: 10.1016/j.anl.2023.04.006. Epub 2023 May 8. Auris Nasus Larynx. 2023. PMID: 37164815
Copy number alteration is an independent prognostic biomarker in triple-negative breast cancer patients.
Nagahashi M, Ling Y, Toshikawa C, Hayashida T, Kitagawa Y, Futamura M, Kuwayama T, Nakamura S, Yamauchi H, Yamauchi T, Kaneko K, Kanbayashi C, Sato N, Tsuchida J, Moro K, Nakajima M, Shimada Y, Ichikawa H, Lyle S, Miyoshi Y, Takabe K, Okuda S, Wakai T. Nagahashi M, et al. Among authors: futamura m. Breast Cancer. 2023 Jul;30(4):584-595. doi: 10.1007/s12282-023-01449-2. Epub 2023 Mar 17. Breast Cancer. 2023. PMID: 36930419
Oncofertility-related psycho-educational therapy for young adult patients with breast cancer and their partners: Randomized controlled trial.
Koizumi T, Sugishita Y, Suzuki-Takahashi Y, Nara K, Miyagawa T, Nakajima M, Sugimoto K, Futamura M, Furui T, Takai Y, Matsumoto H, Yamauchi H, Ohno S, Kataoka A, Kawai K, Fukuma E, Nogi H, Tsugawa K, Suzuki N. Koizumi T, et al. Among authors: futamura m. Cancer. 2023 Aug 15;129(16):2568-2580. doi: 10.1002/cncr.34796. Epub 2023 Apr 21. Cancer. 2023. PMID: 37082910 Clinical Trial.
Proton Pump Inhibitors and Cyclin-Dependent Kinase 4/6 Inhibitors in Patients With Breast Cancer.
Takahashi K, Uozumi R, Mukohara T, Hayashida T, Iwabe M, Iihara H, Kusuhara-Mamishin K, Kitagawa Y, Tsuchiya M, Kitahora M, Nagayama A, Kosaka S, Asano-Niwa Y, Seki T, Ohnuki K, Suzuki A, Ono F, Futamura M, Kawazoe H, Nakamura T. Takahashi K, et al. Among authors: futamura m. Oncologist. 2024 Feb 10:oyae015. doi: 10.1093/oncolo/oyae015. Online ahead of print. Oncologist. 2024. PMID: 38340010 Free article.
Survival advantage of locoregional and systemic therapy in oligometastatic breast cancer: an international retrospective cohort study (OLIGO-BC1).
Imoto S, Wang K, Bi XW, Liu G, Im YH, Im SA, Sim SH, Ueno T, Futamura M, Toi M, Fujiwara Y, Ahn SG, Lee JE, Park YH, Takao S, Oba MS, Kitagawa Y, Nishiyama M. Imoto S, et al. Among authors: futamura m. Breast Cancer. 2023 May;30(3):412-423. doi: 10.1007/s12282-023-01436-7. Epub 2023 Jan 23. Breast Cancer. 2023. PMID: 36689066
Patients Offer Radiofrequency Ablation Therapy for Early Breast Cancer as Local Therapy (PO-RAFAELO) Study under the Patient-proposed Health Services.
Takayama S, Kinoshita T, Shiino S, Jimbo K, Watanabe KI, Fujisawa T, Yamamoto N, Onishi T, Shien T, Ito M, Takahashi M, Futamura M, Aruga T, Kaneko K, Suto A. Takayama S, et al. Among authors: futamura m. JMA J. 2023 Oct 16;6(4):505-512. doi: 10.31662/jmaj.2023-0047. Epub 2023 Oct 2. JMA J. 2023. PMID: 37941717 Free PMC article. Clinical Trial.
Doublet or Triplet Antiemetic Prophylaxis for Nausea and Vomiting Induced by Trastuzumab Deruxtecan: an Open-Label, Randomized, and Multicenter Exploratory Phase 2 Study.
Iihara H, Shimokawa M, Bando H, Niwa Y, Mizuno Y, Kawaguchi Y, Kitahora M, Murakami A, Kawai M, Ishida K, Takeuchi M, Ishihara K, Iyoda T, Nakada T, Ogiso A, Kojima Y, Kumagai F, Sawa A, Mori R, Higuchi K, Furuta T, Kamei Y, Tsuchiya M, Terasaki A, Yamamoto S, Kitazawa M, Okazaki M, Suzuki A, Futamura M. Iihara H, et al. Among authors: futamura m. J Cancer. 2023 Aug 28;14(14):2644-2654. doi: 10.7150/jca.87169. eCollection 2023. J Cancer. 2023. PMID: 37779870 Free PMC article.
90 results